Limited coverage drugs – risankizumab for plaque psoriasis

Last updated on September 26, 2024

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	risankizumab
Strength	75 mg/ 0.83 mL	150 mg/mL
Form	pre-filled syringe (subcutaneous injection)	pre-filled pen (subcutaneous injection)

Special Authority criteria	Approval period
For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form 5380, when prescribed by a dermatologist	First approval: 16 weeks Renewal: 1 year

Special Authority criteria

Approval period

For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form 5380, when prescribed by a dermatologist

First approval: 16 weeks

Renewal: 1 year

Practitioner exemptions

None

Special notes

PharmaCare coverage of risankizumab is limited to 150 mg every 12 weeks at maintenance dosing. 150 mg loading doses are covered at weeks 0, 4 and 16

Special Authority requests

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – risankizumab for plaque psoriasis

Practitioner exemptions

Special notes

Special Authority requests